These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31231974)

  • 21. Healthcare resource use and costs of opioid-induced constipation among non-cancer and cancer patients on opioid therapy: A nationwide register-based cohort study in Denmark.
    Søndergaard J; Christensen HN; Ibsen R; Jarbøl DE; Kjellberg J
    Scand J Pain; 2017 Apr; 15():83-90. PubMed ID: 28850356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation.
    Poelaert J; Koopmans-Klein G; Dioh A; Louis F; Gorissen M; Logé D; Van Op den Bosch J; van Megen YJ
    Clin Ther; 2015 Apr; 37(4):784-92. PubMed ID: 25757607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magnesium hydroxide versus macrogol/electrolytes in the prevention of opioid-induced constipation in incurable cancer patients: study protocol for an open-label, randomized controlled trial (the OMAMA study).
    Kistemaker KRJ; de Graeff A; Crul M; de Klerk G; van de Ven PM; van der Meulen MP; van Zuylen L; Steegers MAH
    BMC Palliat Care; 2023 Mar; 22(1):22. PubMed ID: 36915062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
    Irving G; Pénzes J; Ramjattan B; Cousins M; Rauck R; Spierings EL; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
    J Pain; 2011 Feb; 12(2):175-84. PubMed ID: 21292168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Survey of the Incidence of Constipation in Patients with Chronic Non-cancer Pain Using Opioid Analgesics in Japan.
    Sonohata M; Wada S; Koretaka Y; Morioka Y; Mishima H; Mawatari M
    Pain Ther; 2022 Sep; 11(3):845-859. PubMed ID: 35598289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opioid-induced constipation in chronic pain: Experience with 180 patients.
    Velázquez Rivera I; Velázquez Clavarana L; García Velasco P; Melero Ramos C
    J Opioid Manag; 2019; 15(1):69-76. PubMed ID: 30855724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delphi consensus on strategies in the management of opioid-induced constipation in cancer patients.
    Sarrió RG; Calsina-Berna A; García AG; Esparza-Miñana JM; Ferrer EF; ; Porta-Sales J
    BMC Palliat Care; 2021 Jan; 20(1):1. PubMed ID: 33388041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of naldemedine treatment for opioid-induced constipation in gastrointestinal cancer: a retrospective analysis.
    Nishiba H; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Mogi J; Obayashi K; Minato K
    Ann Palliat Med; 2023 Jul; 12(4):697-707. PubMed ID: 37081703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
    Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient and provider differences in the treatment of opioid-induced constipation: a qualitative study.
    Keller MS; Jusufagic A; Spiegel BMR
    BMC Gastroenterol; 2019 Nov; 19(1):182. PubMed ID: 31718543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study.
    Brenner DM; Argoff CE; Fox SM; Bochenek W; D'Astoli P; Blakesley RE; Reasner DS; O'Dea CR; Cash BD
    Pain; 2020 May; 161(5):1027-1036. PubMed ID: 32310620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of opioid-induced constipation on healthcare resource utilization and costs for cancer pain patients receiving continuous opioid therapy.
    Fine PG; Chen YW; Wittbrodt E; Datto C
    Support Care Cancer; 2019 Feb; 27(2):687-696. PubMed ID: 30056531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and Burden of Illness of Rome IV Chronic Idiopathic Constipation, Opioid-Induced Constipation, and Opioid-Exacerbated Constipation in the United States.
    Liang J; Almario CV; Chey WD; Higgins CS; Spiegel BMR
    Am J Gastroenterol; 2023 Nov; 118(11):2033-2040. PubMed ID: 37335135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes.
    Spierings ELH; Drossman DA; Cryer B; Mazen Jamal M; Losch-Beridon T; Mareya SM; Wang M
    Pain Med; 2018 Jun; 19(6):1184-1194. PubMed ID: 29016868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan.
    Takata K; Nakazawa M; Honda K; Hashimoto S
    Support Care Cancer; 2022 May; 30(5):3943-3954. PubMed ID: 35044484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opioid-induced constipation in mixed chronic pain patients: Prevalence and predictors analysis.
    Samolsky Dekel BG; Sorella MC; Vasarri A; Gori A; Melotti RM
    J Opioid Manag; 2019; 15(5):375-387. PubMed ID: 31849029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
    Ueberall MA; Mueller-Schwefe GH
    Curr Med Res Opin; 2015; 31(7):1413-29. PubMed ID: 25942606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opioid-induced constipation: a stepwise treatment algorithm feasibility study.
    Davies AN; Leach C; Butler C; Patel SD; Shorthose K; Batsari K
    BMJ Support Palliat Care; 2023 Dec; 13(e2):e446-e453. PubMed ID: 34348942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
    Webster LR; Yamada T; Arjona Ferreira JC
    Pain Med; 2017 Dec; 18(12):2350-2360. PubMed ID: 28371937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.
    Webster L; Dhar S; Eldon M; Masuoka L; Lappalainen J; Sostek M
    Pain; 2013 Sep; 154(9):1542-1550. PubMed ID: 23726675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.